Baillie Gifford & CO Kaleido Biosciences, Inc. Transaction History

Baillie Gifford & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$0.05 - $1.7 $36,676 - $1.25 Million	-733,525 Closed	0 $0
Q1 2022 May 05, 2022	BUY	$1.3 - $2.7 $15,616 - $32,435	12,013 Added 1.66%	733,525 $1.21 Million
Q4 2021 Jan 20, 2022	BUY	$2.39 - $6.02 $148,861 - $374,955	62,285 Added 9.45%	721,512 $1.72 Million
Q3 2021 Oct 19, 2021	BUY	$5.36 - $7.99 $4,105 - $6,120	766 Added 0.12%	659,227 $3.6 Million
Q2 2021 Aug 02, 2021	BUY	$5.82 - $8.72 $6,227 - $9,330	1,070 Added 0.16%	658,461 $4.9 Million
Q1 2021 May 06, 2021	BUY	$7.2 - $16.82 $1.57 Million - $3.66 Million	217,391 Added 49.41%	657,391 $5.33 Million
Q1 2019 May 01, 2019	BUY	$12.71 - $15.0 $5.59 Million - $6.6 Million	440,000 New	440,000 $0

2.65K

Ticker KLDO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,622,600
Description
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the tr...

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

Stay updated on Baillie Gifford & CO with notifications on news.